In a study published in Nature on Oct. 11, coinciding with the beginning of IDWeek 2023 in Boston, researchers from Harvard Medical School described EVEscape, a method for anticipating the movements of SARS‑CoV‑2 by predicting potential mutations likely to escape current vaccines and treatments.
Scientists at Egenesis Inc. have transplanted kidneys from genome-edited pigs into cynomolgus monkeys that remained functional for long periods after transplantation. The monkeys, whose own kidneys were removed during the surgery, survived for a median of 176 days after receiving one pig kidney. Maximal survival was just over 2 years. The data were published today in Nature. Egenesis CEO Mike Curtis told reporters that the study has achieved the longest survival to date “using clinically translatable immunosuppression … longer survival has been achieved using really aggressive immunosuppression that really isn’t clinically translatable.”
Small conductance SK (Ca) channel blockers, particularly SK (Ca) 2.3 (SK3; SKCa3; hKCa3) channel blockers, have been described in an Acesion Pharma ApS patent as potentially useful for the treatment of arrhythmia.
Slap Pharmaceuticals LLC have identified new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
An Intra-Cellular Therapies Inc. patent describes new 5-HT2A, μ-opioid, and dopamine D1 and D2 receptor ligands reported to be useful for the treatment of neurological disorders.
Alumis Inc. has patented non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, neurological, autoimmune, inflammatory and endocrine disorders.
Stem Pharm Inc. and Verge Genomics (Verge Analytics Inc.) have established a collaboration to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease.
RSS
